Los Angeles Capital Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Los Angeles Capital Management’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$524K	Sell	5,672 -22,224	-80%	-$2.09M	﹤0.01%	859
2025 Q4	$2.01M	Buy	27,896 +1,964	+8%	+$141K	0.01%	445
2025 Q3	$1.9M	Buy	25,932 +17,380	+203%	+$1.1M	0.01%	518
2025 Q2	$435K	Buy	+8,552	New	+$381K	﹤0.01%	906
2024 Q2	–	Sell	-41,836	Closed	-$1.05M	–	1243
2024 Q1	$1.05M	Buy	41,836 +4,069	+11%	+$112K	﹤0.01%	673
2023 Q4	$1.11M	Sell	37,767 -4,677	-11%	-$142K	﹤0.01%	640
2023 Q3	$1.34M	Buy	42,444 +494	+1%	+$13.5K	0.01%	540
2023 Q2	$1.09M	Buy	+41,950	New	+$1.12M	﹤0.01%	635
2022 Q4	–	Sell	-17,533	Closed	-$368K	–	1245
2022 Q3	$368K	Sell	17,533 -12,087	-41%	-$291K	﹤0.01%	1015
2022 Q2	$576K	Buy	+29,620	New	+$699K	﹤0.01%	912
2022 Q1	–	Sell	-21,575	Closed	-$344K	–	1461
2021 Q4	$344K	Sell	21,575 -835	-4%	-$13K	﹤0.01%	1189
2021 Q3	$446K	Buy	22,410 +1,470	+7%	+$23.9K	﹤0.01%	1111
2021 Q2	$362K	Buy	20,940 +1,666	+9%	+$29.9K	﹤0.01%	1315
2021 Q1	$382K	Buy	+19,274	New	+$369K	﹤0.01%	1337

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Los Angeles Capital Management's MIRM Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Mirum Pharmaceuticals (MIRM) stake by 80% in Q1 2026, selling an estimated $2.09M and leaving 5,672 shares worth $524K. The position accounts for ﹤0.01% of the portfolio, ranked #859.

Los Angeles Capital Management first reported a position in MIRM in Q1 2021 and has held it in 14 quarters since. The position peaked at $2.01M in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

Los Angeles Capital Management held 5,672 shares of Mirum Pharmaceuticals worth $524K as of Q1 2026.
Los Angeles Capital Management sold 22,224 Mirum Pharmaceuticals shares in Q1 2026, an estimated $2.09M.
Mirum Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #859 holding.
Los Angeles Capital Management first reported a position in Mirum Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
Los Angeles Capital Management's Mirum Pharmaceuticals position peaked at $2.01M in Q4 2025.
311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.